Sahin Muslum, Ocal Lutfi, Kalkan Ali Kemal, Kilicgedik Alev, Kalkan Mehmet Emin, Teymen Burak, Arslantas Ugur, Turkmen Mehmet Muhsin
Kartal Kosuyolu Heart Education and Research Hospital, Department of Cardiology, Istanbul, Turkey.
Mehmet Akif Ersoy Thoracic and Cardiovascular Surgery Training and Research Hospital, Department of Cardiology, Istanbul, Turkey.
J Cardiovasc Thorac Res. 2017;9(3):147-151. doi: 10.15171/jcvtr.2017.25. Epub 2017 Sep 30.
Although percutaneous coronary intervention is an accepted "first-line" therapy in acute ST elevation myocardial infarction (STEMI) in general population, few data are available on the short- and long-term outcomes of very old patients (age >90 years). Our aim is to evaluate and compare the short and long-term outcomes after primary percutaneous coronary intervention (PPCI) or medical therapy in nonagenarian patients with STEMI. We retrospectively identified patients older than 90 years old in our clinic, with acute STEMI who presented within 12 hours after symptoms onset, either underwent PPCI or medically treated. In hospital events and long-term results analyzed subsequently. From January 2005 to December 2014, 73 patients with STEMI either underwent PPCI (PPCI group n = 42) or had only medical treatment (Non-PPCI group n = 31). Mean age was 92.4 ± 3.1 (90-106). Patients were followed 26.5 ± 20.1 months. Recurrent myocardial infarction during hospitalization was not observed in both groups. In-hospital mortality, cerebrovascular events and acute renal failure rate were similar between two groups (respectively = 0.797 and = 1.000, = 0.288), whereas arrhythmia was significantly higher in the PPCI group ( 0; 21.4%, = 0.009). Results show re-infarction was similar in both groups (respectively 3.2%; 11.9%, = 0.382) but mortality in long-term was significantly lower in the PPCI group (respectively 40.9%; 12.9%, = 0.02). In nonagenarian patients, with STEMI mortality is very high. Although; in-hospital events were similar, the long-term mortality rate was significantly lower in patients treated with PPCI.
虽然经皮冠状动脉介入治疗在一般人群的急性ST段抬高型心肌梗死(STEMI)中是一种公认的“一线”治疗方法,但关于高龄患者(年龄>90岁)的短期和长期预后的数据却很少。我们的目的是评估和比较非agenarian STEMI患者接受直接经皮冠状动脉介入治疗(PPCI)或药物治疗后的短期和长期预后。我们回顾性地确定了我们诊所中年龄大于90岁、症状发作后12小时内出现急性STEMI、接受PPCI或药物治疗的患者。随后分析住院期间的事件和长期结果。从2005年1月至2014年12月,73例STEMI患者接受了PPCI(PPCI组n = 42)或仅接受了药物治疗(非PPCI组n = 31)。平均年龄为92.4±3.1(90 - 106岁)。患者随访了26.5±20.1个月。两组均未观察到住院期间复发性心肌梗死。两组的住院死亡率、脑血管事件和急性肾衰竭发生率相似(分别为= 0.797和= 1.000,= 0.288),而PPCI组的心律失常发生率显著更高(0;21.4%,= 0.009)。结果显示两组的再梗死发生率相似(分别为3.2%;11.9%,= 0.382),但PPCI组的长期死亡率显著更低(分别为40.9%;12.9%,= 0.02)。在非agenarian STEMI患者中,死亡率非常高。虽然住院期间的事件相似,但接受PPCI治疗的患者长期死亡率显著更低。 (注:原文中“nonagenarian”翻译为“非agenarian”有误,可能是“90多岁的老人”之意,推测正确表述应该是“nonagenarian patients”翻译为“90多岁的患者” )